0001104659-23-024550.txt : 20230223 0001104659-23-024550.hdr.sgml : 20230223 20230223091153 ACCESSION NUMBER: 0001104659-23-024550 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20230223 DATE AS OF CHANGE: 20230223 EFFECTIVENESS DATE: 20230223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lirum Therapeutics, Inc. CENTRAL INDEX KEY: 0001965411 IRS NUMBER: 881228824 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-474079 FILM NUMBER: 23656492 BUSINESS ADDRESS: STREET 1: 590 MADISON AVENUE STREET 2: SUITE 21ST FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: 917-376-2350 MAIL ADDRESS: STREET 1: 590 MADISON AVENUE STREET 2: SUITE 21ST FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 D 1 primary_doc.xml X0708 D LIVE 0001965411 Lirum Therapeutics, Inc. 590 MADISON AVENUE 21ST FLOOR NEW YORK NY NEW YORK 10022 917-376-2350 DELAWARE None None Corporation true 2021 Kenneth Hoberman 590 Madison Avenue 21st Floor New York NY NEW YORK 10022 Executive Officer Director Ivan Bergstein 590 Madison Avenue 21st Floor New York NY NEW YORK 10022 Director Daniel Hume 590 Madison Avenue 21st Floor New York NY NEW YORK 10022 Director Mark Sard 590 Madison Avenue 21st Floor New York NY NEW YORK 10022 Director Biotechnology Decline to Disclose 06b false 2023-02-08 false true false 5000 ThinkEquity LLC 20996 None None 17 STATE STREET 41ST FLOOR NEW YORK NY NEW YORK 10004 AZ ARIZONA CA CALIFORNIA CO COLORADO CT CONNECTICUT FL FLORIDA IL ILLINOIS MA MASSACHUSETTS NJ NEW JERSEY NY NEW YORK VT VERMONT WI WISCONSIN false 10000000 6300000 3700000 true 3 53 359240 0 In addition to cash fees equaling $359,240 Think Equity received Placement Agent Warrants exercisable for 504,000 shares of Lirum common stock. 0 false Lirum Therapeutics, Inc. /s/ Ivan Bergstein Ivan Bergstein Director 2023-02-23